

Atopic Dermatitis - Pipeline Review, H1 2018

<https://marketpublishers.com/r/AE6D39FBF4EEN.html>

Date: February 2018

Pages: 379

Price: US\$ 2,000.00 (Single User License)

ID: AE6D39FBF4EEN

Abstracts

Atopic Dermatitis - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H1 2018, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I, Preclinical, Discovery and Unknown stages are 9, 34, 19, 43, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 3 and 1 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Atopic Dermatitis - Overview

Atopic Dermatitis - Therapeutics Development

Atopic Dermatitis - Therapeutics Assessment

Atopic Dermatitis - Companies Involved in Therapeutics Development

Atopic Dermatitis - Drug Profiles

Atopic Dermatitis - Dormant Projects

Atopic Dermatitis - Discontinued Products

Atopic Dermatitis - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Atopic Dermatitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd.2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.2), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Atopic Dermatitis - Pipeline by AbbVie Inc, H1 2018
Atopic Dermatitis - Pipeline by Abeome Corp, H1 2018
Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2018
Atopic Dermatitis - Pipeline by Aclaris Therapeutics Inc, H1 2018
Atopic Dermatitis - Pipeline by Allergan Plc, H1 2018
Atopic Dermatitis - Pipeline by Amgen Inc, H1 2018
Atopic Dermatitis - Pipeline by Amorepacific Corp, H1 2018
Atopic Dermatitis - Pipeline by AnaptysBio Inc, H1 2018
Atopic Dermatitis - Pipeline by Antibiotx ApS, H1 2018
Atopic Dermatitis - Pipeline by Asana BioSciences LLC, H1 2018
Atopic Dermatitis - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Atopic Dermatitis - Pipeline by Bioleaders Corp, H1 2018
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2018
Atopic Dermatitis - Pipeline by Brickell Biotech Inc, H1 2018
Atopic Dermatitis - Pipeline by Celgene Corp, H1 2018
Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2018
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Clevexel Pharma SAS, H1 2018
Atopic Dermatitis - Pipeline by Cutanea Life Sciences Inc, H1 2018
Atopic Dermatitis - Pipeline by Dermala Inc, H1 2018
Atopic Dermatitis - Pipeline by DURECT Corp, H1 2018
Atopic Dermatitis - Pipeline by Eli Lilly and Co, H1 2018
Atopic Dermatitis - Pipeline by Exicure Inc, H1 2018
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc, H1 2018
Atopic Dermatitis - Pipeline by Galapagos NV, H1 2018
Atopic Dermatitis - Pipeline by Galderma SA, H1 2018
Atopic Dermatitis - Pipeline by Galectin Therapeutics Inc, H1 2018
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2018
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Atopic Dermatitis - Pipeline by Han Wha Pharma Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Heptares Therapeutics Ltd, H1 2018
Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H1 2018
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc, H1 2018
Atopic Dermatitis - Pipeline by Incyte Corp, H1 2018
Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2018
Atopic Dermatitis - Pipeline by Innovation Pharmaceuticals Inc, H1 2018
Atopic Dermatitis - Pipeline by Japan Tobacco Inc, H1 2018
Atopic Dermatitis - Pipeline by Kang Stem Biotech Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by KPI Therapeutics Inc, H1 2018
Atopic Dermatitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Lead Pharma Holding BV, H1 2018
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2018
Atopic Dermatitis - Pipeline by Madam Therapeutics BV, H1 2018
Atopic Dermatitis - Pipeline by MedImmune LLC, H1 2018
Atopic Dermatitis - Pipeline by NeoPharm Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Novan Inc, H1 2018
Atopic Dermatitis - Pipeline by Novartis AG, H1 2018
Atopic Dermatitis - Pipeline by Nuevolution AB, H1 2018
Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H1 2018

Atopic Dermatitis - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Oxagen Ltd, H1 2018
Atopic Dermatitis - Pipeline by Pfizer Inc, H1 2018
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2018
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2018
Atopic Dermatitis - Pipeline by Qurient Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Realm Therapeutics Plc, H1 2018
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Atopic Dermatitis - Pipeline by Sienna Biopharmaceuticals Inc, H1 2018
Atopic Dermatitis - Pipeline by Signum Biosciences Inc, H1 2018
Atopic Dermatitis - Pipeline by Spherium Biomed SL, H1 2018
Atopic Dermatitis - Pipeline by sterna biologicals GmbH & Co KG, H1 2018
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
Atopic Dermatitis - Pipeline by Switch Biotech LLC, H1 2018
Atopic Dermatitis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2018
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals Inc, H1 2018
Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Ltd, H1 2018
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2018
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana SL, H1 2018
Atopic Dermatitis - Pipeline by Xencor Inc, H1 2018
Atopic Dermatitis - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.1), H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.2), H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.3), H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.4), H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.5), H1 2018
Atopic Dermatitis - Dormant Projects, H1 2018 (Contd.6), H1 2018
Atopic Dermatitis - Discontinued Products, H1 2018
Atopic Dermatitis - Discontinued Products, H1 2018 (Contd.1), H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Atopic Dermatitis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc
Abeome Corp
Accolade Pharmaceuticals LLC
Aclaris Therapeutics Inc
Allergan Plc
Amgen Inc
Amorepacific Corp
AnaptysBio Inc
Antibiotx ApS
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Bioleaders Corp
Blueberry Therapeutics Ltd
Brickell Biotech Inc
Celgene Corp
ChironWells GmbH
Chugai Pharmaceutical Co Ltd
Clevixel Pharma SAS
Cutanea Life Sciences Inc
Dermala Inc
DURECT Corp

Eli Lilly and Co
Exicure Inc
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Galderma SA
Galectin Therapeutics Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Han Wha Pharma Co Ltd
Heptares Therapeutics Ltd
iCo Therapeutics Inc.
Immune Pharmaceuticals Inc
Incyte Corp
Inflamalps SA
Innovation Pharmaceuticals Inc
Japan Tobacco Inc
Kang Stem Biotech Co Ltd
KPI Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
Lead Pharma Holding BV
LEO Pharma A/S
Madam Therapeutics BV
MedImmune LLC
NeoPharm Co Ltd
Novan Inc
Novartis AG
Nuevolution AB
Orbis Biosciences Inc
Otsuka Holdings Co Ltd
Oxagen Ltd
Pfizer Inc
Pharis Biotec GmbH
Pharmedartis GmbH
Qurient Co Ltd
Realm Therapeutics Plc
Regeneron Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Signum Biosciences Inc

Spherium Biomed SL
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd
Switch Biotech LLC
TaiwanJ Pharmaceuticals Co Ltd
Thesan Pharmaceuticals Inc
Torrent Pharmaceuticals Ltd
Valeant Pharmaceuticals International Inc
VivaCell Biotechnology Espana SL
Xencor Inc
Zhejiang I-Biological Technology Co Ltd

I would like to order

Product name: Atopic Dermatitis - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/AE6D39FBF4EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AE6D39FBF4EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970